Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNYA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTenaya expands equity plan by 6.5M shares, removes annual cap on evergreen provision
Filed May 29, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
medium
Stockholders approved adding 6.5 million shares (roughly 3% of outstanding) to the 2021 equity plan, increasing the pool available for employee and director compensation grants.
Item 5.07 verify on EDGAR → -
medium
Annual 'evergreen' provision amended to remove the 4 million share annual cap while maintaining 4% yearly increases based on outstanding shares, potentially allowing larger future dilution.
Item 5.07 verify on EDGAR → -
low
Three Class II directors elected to three-year terms through 2029: Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen, all receiving strong majority support.
Item 5.07 verify on EDGAR → -
low
Deloitte & Touche LLP ratified as independent auditor for fiscal 2026 with 98.5% approval, maintaining audit continuity.
Item 5.07 verify on EDGAR →
Summary
Tenaya Therapeutics held its annual stockholder meeting on May 27, 2026, where shareholders approved significant changes to the company's equity compensation program. The most material outcome was the expansion of the 2021 Equity Incentive Plan by 6.5 million shares and the removal of the annual cap on the evergreen provision.
While the evergreen still increases by 4% of outstanding shares each year, eliminating the previous 4 million share ceiling means the company now has more flexibility to grant stock-based compensation as it grows. For retail investors, this matters because equity grants dilute existing shareholders.
The 6.5 million share addition represents about 3% immediate dilution, and the uncapped evergreen could accelerate future dilution if the company's share count grows substantially. This is common for biotech companies that rely heavily on equity to attract talent, but investors should monitor how aggressively management uses these shares. Watch the next proxy statement to see actual grant patterns and whether dilution accelerates compared to historical levels. The meeting also included routine governance items: three directors were re-elected and the auditor was ratified, both with strong support.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The amendments to the A&R 2021 Equity Incentive Plan included (1) a one-time increase to the number of shares of common stock reserved for issuance by approximately 3% of the Company’s outstanding shares (6,509,966 shares), (2) an amendment to the annual “evergreen” provision to remove the annual limit of 4 million shares, while maintaining the annual increase at 4% of the Company’s outstanding shares, and (3) limiting the number of shares that can be issued as incentive stock options under the plan.
The company's stockholders approved amendments to the 2021 equity plan on May 27, 2026. The plan now has 6,509,966 additional shares available for grants (about 3% of outstanding shares). The annual evergreen provision previously capped at 4 million shares now has no cap, though it still increases by 4% of outstanding shares annually. The plan also now limits incentive stock option issuance.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Annual meeting held May 27, 2026: three Class II directors elected, auditor ratified, and amended equity plan approved.
Added in current filing · verify on EDGAR →
For | Against | Abstain | Broker Non-Votes | 67,356,607 | 20,575,701 | 2,356,444 | 48,606,132
The stockholders approved the amendment and restatement of the Company’s 2021 Equity Incentive Plan.
Stockholders approved amendments to the 2021 Equity Incentive Plan with 67.4 million votes for and 20.6 million against. The approval allows the company to continue granting equity compensation to employees and directors, though the filing does not specify what changes were made to the plan.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
For | Against | Abstain | Broker Non-Votes | 135,650,321 | 2,023,657 | 1,220,906 | 0
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026 with overwhelming support (135.7 million votes for vs. 2.0 million against). This is a routine annual vote confirming continuity in external audit oversight.
Event · Item 9.01 — Financial Statements and Exhibits
Tenaya Therapeutics filed an amended and restated 2021 Equity Incentive Plan, a routine procedural update with no material business impact disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Amended and Restated 2021 Equity Incentive Plan
The company filed an amended and restated version of its 2021 Equity Incentive Plan. This is a routine procedural filing that typically reflects updates to share reserve amounts, plan terms, or administrative provisions approved by shareholders. Without the full exhibit text, the specific changes cannot be determined, but such amendments are common corporate governance actions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify